

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEAtty. Docket No. **4401.214-US**Serial No. **To be assigned**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant **Thomas Dyrberg, et al.**

(Use several sheets if necessary)

Filing Date **May 2, 2001**Group **To be assigned**

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,422,339	06/06/95	Eisenbarth			

J1046 U.S. PTO  
 09/847623  
 05/02/01

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	95/24216	09/14/95	PCT				
	94/23737	10/27/94	PCT				
	92/06704	04/30/92	PCT				
	97/09061	03/13/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ziegler et al., "Prophylactic Insulin Treatment in Relatives at High Risk for Type 1
		Diabetes", Diabetes/Metabolism Reviews, Vol. 9, No. 4, 289-293 (1993),
		pp. 289-293.

EXAMINER

DATE CONSIDERED


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No.: 4401.214-us

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
EXPRESS MAIL CERTIFICATE**

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231



Re: U.S. Patent Application for  
Title: Prevention Of A Disease Having The Characteristics of Diabetes  
Applicants: Thomas Dyrberg, et al.

Sir:

Express Mail Label No. EL636736632US

Date of Deposit: May 2, 2001

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Copy of Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Information Disclosure Statement
6. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, DC 20231.

Sylvia Gonzalez

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10017  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 4401.214-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Dyrberg et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: May 2, 2001

Examiner: To be assigned

For: Prevention Of A Disease Having The Characteristics Of Diabetes

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 09/319,138 filed December 19, 1997, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. WO 95/24216
2. WO 94/23737
3. WO 92/06704




4. U.S. 5,422,339
5. Ziegler et al., "Prophylactic Insulin Treatment in Relatives at High Risk For Type 1 Diabetes", Diabetes/Metabolism Reviews, Vol. 9, No. 4, 289-293 (1993), pp. 289-293.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due.

Respectfully submitted,

Date: 2 May 2001

  
Valeta A. Gregg, Reg. No. 35,427  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE